Spero Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $88.3M | $112.6M |
| FY2022 | — | $75.9M | $109.1M |
| FY2023 | — | $106.9M | $76.3M |
| FY2024 | — | $46.1M | $52.9M |
| FY2025 | — | $59.0M | $40.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $88.3M | $112.6M |
| FY2022 | — | $75.9M | $109.1M |
| FY2023 | — | $106.9M | $76.3M |
| FY2024 | — | $46.1M | $52.9M |
| FY2025 | — | $59.0M | $40.3M |